MiMedx Group, Inc.

NASDAQ:MDXG

Biotechnology

Healthcare
$3.18 +2.22%

+$0.08 today

Market cap
$464.04M
Beta
1.46
P/E (TTM)
17.8
EPS (TTM)
$0.21
52W Low $3.03High $7.99

Volume 1.51M

Average 1.55M

MDXG Pre-Tax Margin

Income before tax as a percentage of revenue.

MiMedx Group, Inc.NASDAQ: MDXG

Pre-Tax Margin · Q1 FY2026 · quarter ended Mar 2026

Pre-tax margin narrows to -26.0%

Pre-tax margin was -26.0% in Q1 FY2026, down 35.8 pp from a year earlier. On a trailing-twelve-month basis it was 10.9%, down 4.6 pp year over year. Over 3 fiscal years it widened by 23.2 pp.

Context

  • Pre-tax margin widened in 2 of the last 3 fiscal years.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-26.0%-44.4 pp QoQ
Last fiscal yearDec 2025
15.8%-0.6 pp YoY
LTMMar 2026
10.9%-4.6 pp YoY
Pre-Tax Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-35.8 pp——
1 year-0.6 pp——
3 years+23.2 pp——
5 years——
10 years——

Pre-Tax Margin history

Percent of revenue · from the income statement

Latest · FY2025
15.8%
Year-over-year change
-0.6pp

Pre-Tax Margin vs competitors

How MDXG compares with its peers on the latest reported figures

  • MDXG's LTM Mar 2026 pre-tax margin of 10.9% is the 2nd highest of the 8 companies compared; the peer median is -62.7%.
  • Its year-over-year change of -4.6 pp is the 5th highest of 8, against a peer median of +6.1 pp.
  • Over three fiscal years its change of +23.2 pp compares with a peer median of +3.8 pp.
MDXG Competitors Peer median
Pre-Tax Margin for MDXG and competitors
Company Period LTM level YoY 3-year change
BSEMBioStem Technologies, Inc.LTM Jun 202639.2% +31.7 pp+102.6 pp
MDXGMiMedx Group, Inc.LTM Mar 202610.9% -4.6 pp+23.2 pp
ORGOOrganogenesis Holdings Inc.LTM Mar 20260.8% +6.1 pp+3.8 pp
SMTISanara MedTech Inc.LTM Mar 2026-1.8% +7.8 pp+30.0 pp
RCELAVITA Medical, Inc.LTM Mar 2026-62.7% +16.9 pp+9.5 pp
MDWDMediWound Ltd.LTM Mar 2026-179.3% -69.0 pp-66.1 pp
CELUCelularity Inc.LTM Dec 2025-345.4% -238.7 pp-424.5 pp
LCTXLineage Cell Therapeutics, Inc.LTM Mar 2026-468.9% -299.7 pp-296.1 pp
Peer median (excluding MDXG) -62.7%+6.1 pp+3.8 pp

Competitors are the stored peer set for MDXG. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue242.02M267.84M321.48M348.88M418.63M
Cost of Revenue39.63M48.32M54.63M60.07M73.01M
Gross Profit202.39M219.53M266.84M288.81M345.62M
Gross Margin83.6%82.0%83.0%82.8%82.6%
Research & Development9.93M12.7M12.67M12.34M15.1M
Selling, General & Admin194.85M220.85M216.3M216.39M266.19M
Operating Expenses209.44M234.25M229.73M229.94M281.29M
Depreciation & Amortization5.18M4.05M3.43M6.04M14.88M
EBITDA(1.89M)(10.69M)40.52M65.35M82.93M
EBITDA Margin-0.8%-4.0%12.6%18.7%19.8%
Operating Income(7.05M)(14.73M)37.12M58.87M63.89M
Operating Margin-2.9%-5.5%11.5%16.9%15.3%
Interest Income00004.72M
Interest Expense4.98M5.02M6.46M1.01M1.78M
Other Income / Expenses(5M)(5.02M)(6.48M)(1.57M)2.38M
Income Before Tax(12.05M)(19.75M)30.63M57.29M66.26M
Pre-Tax Margin-5.0%-7.4%9.5%16.4%15.8%
Income Tax Expense247K206K(36.81M)15.3M17.68M
Net Income(12.3M)(30.2M)67.44M42.42M48.58M
Net Margin-5.1%-11.3%21.0%12.2%11.6%
EPS (Basic)(0.09)(0.27)0.480.290.33
EPS (Diluted)(0.09)(0.27)0.380.280.32
Weighted Avg Shares110.35M112.91M116.5M146.98M147.79M
Weighted Avg Shares (Diluted)110.35M112.91M145.96M149.05M149.72M

MiMedx Group, Inc.

NASDAQ:MDXG

Intrinsic Alpha fair value

Locked

Current Price

$3.18

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.